Kyoto iCAP has made an additional investment of 500 million yen into Orizuru Therapeutics, supporting its innovative regenerative medicine efforts utilizing iPS cell technology.

Overview of Orizuru Therapeutics

Orizuru Therapeutics, established on April 9, 2021, is a biotechnology company that develops regenerative medicine products and innovative iPS cell-related technologies, leveraging research成果 from Kyoto University. Headquartered in Sakyo-ku, Kyoto, the company aims to advance clinical development and manufacturing of groundbreaking regenerative products using iPS cell-derived cardiomyocytes and pancreatic islet cells.

Recently, Orizuru raised approximately 3.3 billion yen in its Series B round through third-party allotment, bringing the total funds raised through this method to over 9.5 billion yen. With additional grants from the AMED (Japan Agency for Medical Research and Development) program, Orizuru's total fundraising since its inception exceeds 10 billion yen. This infusion of capital will enable Orizuru to expedite the development and clinical trials of its promising regenerative medicine products.

Industry Overview in Japan

The biotechnology industry in Japan has been experiencing significant growth, fueled by advancements in regenerative medicine and stem cell research. As a global leader in iPS cell technology, Japan is well-positioned to capitalize